Platform presentations of selected Solid Tumors abstracts.
ST132 - The Impact of Clinical Molecular Testing and Precision Medicine in Thyroid Cancer
Dora Dias-Santagata, PhD, FACMG, Massachusetts General Hospital - Harvard Medical School, Boston, MA, USA
ST009 - Improved Detection of MET Exon 14 Skipping Mutations in Lung Adenocarcinoma with Combined DNA/RNA Testing and Refined Analysis Methods
David Manthei, MD, PhD, University of Michigan, Department of Pathology, Ann Arbor, MI, USA
ST010 - Detection of Point Mutations in Paediatric Low Grade Glioma (PLGG) and Diffuse Intrinsic Pontine Glioma (DIPG) Patients: Validation of a Novel Liquid Biopsy Assay
Monique Johnson, MSc, The Hospital for Sick Children, Toronto, Ontario, Canada
ST015 - Clonal hematopoiesis mutations in plasma cfDNA RAS/BRAF genotyping of metastatic colorectal cancer
Fei Huang, Zhongshan Hospital, Fudan University, Shanghai, China
ST094 - STK11 Loss of Function Variants Mediate Immune Evasion in NSCLC via Dysregulation of the FAK/Hippo Signaling Axis and Subsequent Alterations in Tumor-Intrinsic Cytokine Expression
Liam Donnelly, MD, University of Vermont Medical Center, Burlington, VT, USA
Objectives:
- Analyze presentations of abstracts highlighted by the Solid Tumors Subdivision leadership as particularly significant.
- Evaluate the scientific merit and significance of these selected studies through further discussion with the authors.
Duration: 1.25 hr
Recording Date: November 9, 2019
CME/CMLE credit: 1.25 hr
Last day to purchase course and CE claim credit: December 24, 2022
